| | The third dose BNT162b2 Vaccine helped in 50% serum neutralization titers against wild-type (USA-WA1/2020) severe
acute respiratory syndrome coronavirus 2 (SARSCoV-2) and a recombinant beta variant strain. A third dose may extend protection and broaden it even more, according to the safety and immunogenicity of a booster dose of BNT162b2 given 7 to 9 months after the initial two-dose series. | ✍ | 34525276
(N Engl J Med)
| PMID | 34525276 Date of Publishing: 2021 Sep 15 | | Title | SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | | Author(s) name | Falsey AR, Frenck RW Jr et al. | | Journal | N Engl J Med | | Impact factor | 37.91 Citation count: 81 | | Date of Entry | 2022 Aug 26 |
×
| NLM format |
| Falsey AR, Frenck RW Jr, Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R, Swanson KA, Xu X, Koury K, Kalina W, Cooper D, Zou J, Xie X, Xia H, Türeci Ö, Lagkadinou E, Tompkins KR, Shi PY, Jansen KU, Şahin U, Dormitzer PR, Gruber WC. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021 Oct 21;385(17):1627-1629. PMID:34525276 |
|
| | Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) after 6 months of follow-up among subjects who had no indication of prior SARS-CoV-2 infection. Vaccine efficacy began to deteriorate gradually. Vaccine efficacy of 86 to 100 percent was observed across nations and in people with a wide range of ages, sexes, race or ethnic groupings, and risk factors for Covid-19 among participants who had no prior infection with SARS-CoV-2. The vaccine was 96.7% effective against severe illness (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was prevalent, vaccine effectiveness was reported to be 100% (95% confidence interval, 53.5 to 100). | ✍ | 34525277
(N Engl J Med)
| PMID | 34525277 Date of Publishing: 2021 Sep 15 | | Title | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | | Author(s) name | Thomas SJ, Moreira ED Jr et al. | | Journal | N Engl J Med | | Impact factor | 37.91 Citation count: 224 | | Date of Entry | 2022 Jun 20 |
×
| NLM format |
| Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Nov 4;385(19):1761-1773. PMID:34525277 |
|